$APDN
APPLIED DNA SCIENCES INC

2024 Q2 Form 10-Q Financial Statement

#000141057824000733 Filed on May 10, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $797.5K $929.6K
YoY Change -72.66% -78.91%
Cost Of Revenue $552.3K $634.0K
YoY Change -66.49% -75.62%
Gross Profit $245.2K $295.7K
YoY Change -80.68% -83.64%
Gross Profit Margin 30.75% 31.8%
Selling, General & Admin $2.679M $3.000M
YoY Change -18.63% -14.83%
% of Gross Profit 1092.39% 1014.78%
Research & Development $913.0K $913.2K
YoY Change 9.2% -7.64%
% of Gross Profit 372.31% 308.88%
Depreciation & Amortization $134.1K $186.3K
YoY Change -61.58% -45.91%
% of Gross Profit 54.7% 63.02%
Operating Expenses $3.592M $3.913M
YoY Change -13.0% -13.26%
Operating Profit -$3.347M -$3.618M
YoY Change 17.05% 33.79%
Interest Expense $36.30K $15.35K
YoY Change 35.55% 321.7%
% of Operating Profit
Other Income/Expense, Net -$101.00 $4.581K
YoY Change -97.09% 593.04%
Pretax Income $1.850M -$4.494M
YoY Change -159.39% -915.31%
Income Tax $0.00 $0.00
% Of Pretax Income 0.0%
Net Earnings $1.880M -$4.470M
YoY Change -160.64% -859.84%
Net Earnings / Revenue 235.71% -480.89%
Basic Earnings Per Share $0.47 -$5.31
Diluted Earnings Per Share $0.47 -$5.31
COMMON SHARES
Basic Shares Outstanding 984.7K 16.98M
Diluted Shares Outstanding 4.014M 871.3K

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.44M $3.150M
YoY Change -2.92% -74.37%
Cash & Equivalents $10.44M $3.150M
Short-Term Investments
Other Short-Term Assets $416.4K $470.3K
YoY Change -20.66% -38.0%
Inventory $469.9K $335.9K
Prepaid Expenses
Receivables $513.9K $408.9K
Other Receivables $0.00 $0.00
Total Short-Term Assets $11.84M $4.365M
YoY Change -3.25% -71.62%
LONG-TERM ASSETS
Property, Plant & Equipment $530.7K $367.8K
YoY Change -54.56% -76.65%
Goodwill
YoY Change
Intangibles $2.699M $2.699M
YoY Change
Long-Term Investments
YoY Change
Other Assets $750.0K $750.0K
YoY Change -26.88% 0.0%
Total Long-Term Assets $4.848M $4.811M
YoY Change 36.59% 26.74%
TOTAL ASSETS
Total Short-Term Assets $11.84M $4.365M
Total Long-Term Assets $4.848M $4.811M
Total Assets $16.69M $9.176M
YoY Change 5.7% -52.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.599M $1.128M
YoY Change 52.05% -31.53%
Accrued Expenses $1.375M $1.444M
YoY Change -12.05% -16.29%
Deferred Revenue $51.29K $51.29K
YoY Change -81.41% -81.9%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.026M $2.623M
YoY Change 4.65% -28.24%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $745.9K $6.044M
YoY Change -86.92% 8.86%
Total Long-Term Liabilities $745.9K $6.044M
YoY Change -86.92% 8.86%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.026M $2.623M
Total Long-Term Liabilities $745.9K $6.044M
Total Liabilities $4.456M $9.351M
YoY Change -48.16% 1.56%
SHAREHOLDERS EQUITY
Retained Earnings -$306.4M -$308.3M
YoY Change 2.52% 4.23%
Common Stock $318.8M $308.2M
YoY Change 4.14% 0.8%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $12.39M -$48.15K
YoY Change
Total Liabilities & Shareholders Equity $16.69M $9.176M
YoY Change 5.7% -52.15%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income $1.880M -$4.470M
YoY Change -160.64% -859.84%
Depreciation, Depletion And Amortization $134.1K $186.3K
YoY Change -61.58% -45.91%
Cash From Operating Activities -$3.495M -$3.210M
YoY Change 155.23% -1597.27%
INVESTING ACTIVITIES
Capital Expenditures $21.85K $14.83K
YoY Change -9.71% -72.71%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$21.85K -$14.83K
YoY Change -86.5% -72.71%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 10.81M 3.015M
YoY Change
NET CHANGE
Cash From Operating Activities -3.495M -3.210M
Cash From Investing Activities -21.85K -14.83K
Cash From Financing Activities 10.81M 3.015M
Net Change In Cash 7.293M -209.4K
YoY Change -576.33% -230.83%
FREE CASH FLOW
Cash From Operating Activities -$3.495M -$3.210M
Capital Expenditures $21.85K $14.83K
Free Cash Flow -$3.516M -$3.225M
YoY Change 152.37% -2114.88%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
dei Entity Central Index Key
EntityCentralIndexKey
0000744452
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2024Q1 apdn Fair Value Assets Level2 To Level1 Transfers Amount1
FairValueAssetsLevel2ToLevel1TransfersAmount1
0
CY2024Q1 apdn Fair Value Liabilities Level2 To Level1 Transfers Amount1
FairValueLiabilitiesLevel2ToLevel1TransfersAmount1
0
CY2024Q1 apdn Fair Value Liabilities Level1 To Level2 Transfers Amount1
FairValueLiabilitiesLevel1ToLevel2TransfersAmount1
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36745
dei Entity Registrant Name
EntityRegistrantName
Applied DNA Sciences, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
59-2262718
dei Entity Address Address Line1
EntityAddressAddressLine1
50 Health Sciences Drive
dei Entity Address City Or Town
EntityAddressCityOrTown
Stony Brook
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
11790
dei City Area Code
CityAreaCode
631
dei Local Phone Number
LocalPhoneNumber
240-8800
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
dei Trading Symbol
TradingSymbol
APDN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
984728
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3149640
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7151800
CY2024Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
75000
CY2023Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
75000
CY2024Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
408853
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
255502
CY2024Q1 us-gaap Inventory Net
InventoryNet
335943
CY2023Q3 us-gaap Inventory Net
InventoryNet
330027
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
470284
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
389241
CY2024Q1 us-gaap Assets Current
AssetsCurrent
4364720
CY2023Q3 us-gaap Assets Current
AssetsCurrent
8126570
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
367821
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
838270
CY2024Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
750000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
750000
CY2024Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2698975
CY2023Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2698975
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
994111
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1237762
CY2024Q1 us-gaap Assets
Assets
9175627
CY2023Q3 us-gaap Assets
Assets
13651577
CY2024Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2050035
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2270388
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
521719
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
498598
CY2024Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
51285
CY2023Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
76435
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2623039
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2845421
CY2024Q1 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
31467
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
31467
CY2024Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
194000
CY2023Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
194000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
472391
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
739162
CY2024Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
684115
CY2023Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
684115
CY2024Q1 apdn Common Warrant Liability Noncurrent
CommonWarrantLiabilityNoncurrent
5346000
CY2023Q3 apdn Common Warrant Liability Noncurrent
CommonWarrantLiabilityNoncurrent
4285000
CY2024Q1 us-gaap Liabilities
Liabilities
9351012
CY2023Q3 us-gaap Liabilities
Liabilities
8779165
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
863068
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
863068
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
682926
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
682926
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
864
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
683
CY2024Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
308206796
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
307397623
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-308255808
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-302447147
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-48148
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
4951159
CY2024Q1 us-gaap Minority Interest
MinorityInterest
-127237
CY2023Q3 us-gaap Minority Interest
MinorityInterest
-78747
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-175385
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
4872412
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9175627
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13651577
CY2024Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
929631
CY2023Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
4407614
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1820795
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
9670366
CY2024Q1 us-gaap Cost Of Revenue
CostOfRevenue
633980
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
2600179
us-gaap Cost Of Revenue
CostOfRevenue
1294047
us-gaap Cost Of Revenue
CostOfRevenue
5485248
CY2024Q1 us-gaap Gross Profit
GrossProfit
295651
CY2023Q1 us-gaap Gross Profit
GrossProfit
1807435
us-gaap Gross Profit
GrossProfit
526748
us-gaap Gross Profit
GrossProfit
4185118
CY2024Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3000208
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3522715
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6084557
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6148072
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
913194
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
988744
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1849009
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1960048
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
3913402
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
4511459
us-gaap Operating Expenses
OperatingExpenses
7933566
us-gaap Operating Expenses
OperatingExpenses
8108120
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3617751
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2704024
us-gaap Operating Income Loss
OperatingIncomeLoss
-7406818
us-gaap Operating Income Loss
OperatingIncomeLoss
-3923002
CY2024Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
15352
CY2023Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
3639
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
48676
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
7325
CY2024Q1 apdn Transaction Cost Allocated To Warrant Liabilities
TransactionCostAllocatedToWarrantLiabilities
-633198
apdn Transaction Cost Allocated To Warrant Liabilities
TransactionCostAllocatedToWarrantLiabilities
-633198
CY2024Q1 apdn Unrealized Gain On Change In Fair Value Of Warrants
UnrealizedGainOnChangeInFairValueOfWarrants
1765000
CY2023Q1 apdn Unrealized Gain On Change In Fair Value Of Warrants
UnrealizedGainOnChangeInFairValueOfWarrants
3250900
apdn Unrealized Gain On Change In Fair Value Of Warrants
UnrealizedGainOnChangeInFairValueOfWarrants
4404000
apdn Unrealized Gain On Change In Fair Value Of Warrants
UnrealizedGainOnChangeInFairValueOfWarrants
613100
CY2024Q1 apdn Unrealized Loss On Change In Fair Value Of Warrants
UnrealizedLossOnChangeInFairValueOfWarrants
-394000
apdn Unrealized Loss On Change In Fair Value Of Warrants
UnrealizedLossOnChangeInFairValueOfWarrants
-394000
CY2024Q1 apdn Loss On Issuance Of Warrants
LossOnIssuanceOfWarrants
1633767
apdn Loss On Issuance Of Warrants
LossOnIssuanceOfWarrants
1633767
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4581
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
661
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-8957
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
9507
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4493783
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
551176
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5624064
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3293070
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-4493783
CY2023Q1 us-gaap Profit Loss
ProfitLoss
551176
us-gaap Profit Loss
ProfitLoss
-5624064
us-gaap Profit Loss
ProfitLoss
-3293070
CY2024Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-23309
CY2023Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-37167
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-48490
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-38041
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-4470474
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
588343
us-gaap Net Income Loss
NetIncomeLoss
-5575574
us-gaap Net Income Loss
NetIncomeLoss
-3255029
CY2024Q1 apdn Deemed Dividend Related To Warrant Modifications
DeemedDividendRelatedToWarrantModifications
155330
apdn Deemed Dividend Related To Warrant Modifications
DeemedDividendRelatedToWarrantModifications
233087
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4625804
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
588343
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5808661
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3255029
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.31
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.31
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.91
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.91
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-7.47
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-7.47
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.04
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.04
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
871319
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
871319
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
645426
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
645426
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
777495
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
777495
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
645426
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
645426
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
12908939
CY2022Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
93748
CY2022Q4 us-gaap Profit Loss
ProfitLoss
-3844246
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9158441
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
258604
CY2023Q1 us-gaap Profit Loss
ProfitLoss
551176
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9968221
us-gaap Income Taxes Paid
IncomeTaxesPaid
0
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
4872412
CY2023Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
340705
CY2023Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
-45566
CY2023Q4 us-gaap Profit Loss
ProfitLoss
-1130281
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
4128402
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
18831
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
171004
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-4493783
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-175385
us-gaap Profit Loss
ProfitLoss
-5624064
us-gaap Profit Loss
ProfitLoss
-3293070
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
485277
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
683422
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
6083
apdn Unrealized Gain On Change In Fair Value Of Warrants
UnrealizedGainOnChangeInFairValueOfWarrants
4404000
apdn Unrealized Gain On Change In Fair Value Of Warrants
UnrealizedGainOnChangeInFairValueOfWarrants
613100
apdn Unrealized Loss On Change In Fair Value Of Warrants
UnrealizedLossOnChangeInFairValueOfWarrants
-394000
apdn Registered Direct Offering Costs
RegisteredDirectOfferingCosts
633198
apdn Loss On Issuance Of Warrants
LossOnIssuanceOfWarrants
1633767
us-gaap Share Based Compensation
ShareBasedCompensation
511709
us-gaap Share Based Compensation
ShareBasedCompensation
352352
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-290022
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
153350
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1389855
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
5916
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-236159
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
81043
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-398523
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-332100
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-746495
apdn Increase Decrease In Deferred Revenues
IncreaseDecreaseInDeferredRevenues
-25150
apdn Increase Decrease In Deferred Revenues
IncreaseDecreaseInDeferredRevenues
-280259
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6967672
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2168718
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
45000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
14828
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
54339
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-14828
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-9339
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2980340
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2980340
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4002160
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2178057
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7901800
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15215285
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3899640
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13037228
us-gaap Interest Paid Net
InterestPaidNet
0
us-gaap Interest Paid Net
InterestPaidNet
0
us-gaap Income Taxes Paid
IncomeTaxesPaid
0
apdn Capitalized Transaction Costs Included In Accounts Payable
CapitalizedTransactionCostsIncludedInAccountsPayable
111747
apdn Deemed Dividend Warrant Modifications
DeemedDividendWarrantModifications
233087
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1545916
apdn Property Plant And Equipment Acquired And Included In Accounts Payable
PropertyPlantAndEquipmentAcquiredAndIncludedInAccountsPayable
20321
apdn Number Of Primary Markets That Use Company S Technologies
NumberOfPrimaryMarketsThatUseCompanySTechnologies
3
us-gaap Profit Loss
ProfitLoss
-5624064
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-6967672
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3149640
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The most significant estimates include revenue recognition, recoverability of long-lived assets, including the values assigned to intangible assets and property and equipment, fair value calculations for warrants, contingencies, and management’s anticipated liquidity. Management reviews its estimates on a regular basis and the effects of any material revisions are reflected in the consolidated financial statements in the period they are deemed necessary. Accordingly, actual results could differ from those estimates. </p>
CY2024Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
929631
CY2023Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
4407614
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1820795
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
9670366
us-gaap Contract With Customer Liability Increase Decrease For Contract Acquired In Business Combination
ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination
25150
CY2024Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
0
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
40035
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3149640
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7151800
CY2024Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
750000
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
750000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3899640
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7901800
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
934429
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
934429
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
489228
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
489228
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Concentrations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and trade receivables. The Company places its cash and cash equivalents with high credit quality institutions. At times, such investments may be in excess of the FDIC insurance limit. As of March 31, 2024, the Company had cash and cash equivalents of approximately $2.8 million in excess of the FDIC insurance limit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company’s revenues earned from sale of products and services for the three and six-month periods ended March 31, 2024 included an aggregate of 24% and 25% from one customer, respectively within the MDx Testing Services segment and an aggregate of 28% and 14%, respectively from one customer within the Therapeutic DNA Production Services segment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company’s revenues earned from sale of products and services for the three and six-month periods ended March 31, 2023 included an aggregate of 85% and 84%, respectively, from two customers within the MDx Testing Services segment. One customer accounted for 44% of the Company’s accounts receivable at March 31, 2024 and three customers accounted for 60% of the Company’s accounts receivable at September 30, 2023.</p>
CY2024Q1 us-gaap Time Deposits At Or Above Fdic Insurance Limit
TimeDepositsAtOrAboveFDICInsuranceLimit
2800000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2024Q1 apdn Fair Value Assets Level1 To Level2 Transfers Amount1
FairValueAssetsLevel1ToLevel2TransfersAmount1
0
CY2024Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
167252
CY2023Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
212079
CY2024Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
15006
CY2023Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
19859
CY2024Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
153685
CY2023Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
98089
CY2024Q1 us-gaap Inventory Net
InventoryNet
335943
CY2023Q3 us-gaap Inventory Net
InventoryNet
330027
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1127763
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1072161
CY2024Q1 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
807100
CY2023Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1138235
CY2024Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
115172
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
59992
CY2024Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2050035
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2270388
CY2024Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
12.18
CY2024Q1 apdn Threshold Period For Filing Of Registration Statement On Form S3 From Date Of Purchase Agreements
ThresholdPeriodForFilingOfRegistrationStatementOnFormS3FromDateOfPurchaseAgreements
P45D
CY2024Q1 apdn Threshold Period To Use Commercially Reasonable Efforts To Cause Registration Statement To Become Effective From Closing Of Purchase Agreements
ThresholdPeriodToUseCommerciallyReasonableEffortsToCauseRegistrationStatementToBecomeEffectiveFromClosingOfPurchaseAgreements
P90D
apdn Registered Direct Offering Costs
RegisteredDirectOfferingCosts
633198
CY2024Q1 apdn Registered Direct Offering Costs
RegisteredDirectOfferingCosts
633198
CY2024Q1 apdn Class Of Warrant Or Right Sale Price Per Share
ClassOfWarrantOrRightSalePricePerShare
12.18
CY2024Q1 apdn Number Of Warrants Held By Other Investors Not Participate In Offering
NumberOfWarrantsHeldByOtherInvestorsNotParticipateInOffering
2904
CY2024Q1 apdn Class Of Warrant Or Right Sale Price Per Share
ClassOfWarrantOrRightSalePricePerShare
12.18
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 apdn Maximum Aggregate Offering Price For Sale Of Stock
MaximumAggregateOfferingPriceForSaleOfStock
6397939
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
4501
us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
64397
apdn Capitalized Transaction Costs For Asset Purchase Transaction Written Off
CapitalizedTransactionCostsForAssetPurchaseTransactionWrittenOff
217000
CY2024Q1 apdn Capitalized Transaction Costs For Asset Purchase Transaction Written Off
CapitalizedTransactionCostsForAssetPurchaseTransactionWrittenOff
217000
apdn Change In Deemed Dividend Related To Warrant Modification
ChangeInDeemedDividendRelatedToWarrantModification
77757
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
261030
CY2023Q3 apdn Weighted Average Price Per Share Warrant Outstanding
WeightedAveragePricePerShareWarrantOutstanding
72.00
apdn Class Of Warrant Or Right Granted
ClassOfWarrantOrRightGranted
876708
apdn Weighted Average Price Per Share Warrant Granted
WeightedAveragePricePerShareWarrantGranted
12.00
apdn Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
150
apdn Weighted Average Price Per Share Warrant Exercised
WeightedAveragePricePerShareWarrantExercised
112.00
apdn Class Of Warrant Or Right Forfeitures And Expirations
ClassOfWarrantOrRightForfeituresAndExpirations
191721
apdn Weighted Average Price Per Share Warrant Cancelled Or Expired
WeightedAveragePricePerShareWarrantCancelledOrExpired
57.00
CY2024Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
945867
CY2024Q1 apdn Weighted Average Price Per Share Warrant Outstanding
WeightedAveragePricePerShareWarrantOutstanding
18.20
apdn Area Of Property Under Operating Lease
AreaOfPropertyUnderOperatingLease
30000
CY2023Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P3Y
CY2023Q1 apdn Area Of Laboratory Space
AreaOfLaboratorySpace
2500
CY2017Q4 apdn Lease For Satellite Testing
LeaseForSatelliteTesting
1108
CY2017Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P3Y
CY2017Q4 apdn Base Rent During Initial Lease Term
BaseRentDuringInitialLeaseTerm
6500
CY2024Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
180589
us-gaap Operating Lease Expense
OperatingLeaseExpense
355008
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2024Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
929631
CY2024Q1 us-gaap Gross Profit
GrossProfit
295651
CY2023Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
4407614
CY2023Q1 us-gaap Gross Profit
GrossProfit
1807435
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1820795
us-gaap Gross Profit
GrossProfit
526748
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
9670366
us-gaap Gross Profit
GrossProfit
4185118
CY2024Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
15352
CY2023Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
3639
CY2024Q1 apdn Unrealized Gain On Change In Fair Value Of Warrants
UnrealizedGainOnChangeInFairValueOfWarrants
1765000
CY2023Q1 apdn Unrealized Gain On Change In Fair Value Of Warrants
UnrealizedGainOnChangeInFairValueOfWarrants
3250900
CY2024Q1 apdn Unrealized Loss On Change In Fair Value Of Warrants
UnrealizedLossOnChangeInFairValueOfWarrants
-394000
CY2024Q1 apdn Transaction Cost Allocated To Warrant Liabilities
TransactionCostAllocatedToWarrantLiabilities
-633198
CY2024Q1 apdn Loss On Issuance Of Warrants
LossOnIssuanceOfWarrants
1633767
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4581
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
661
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4493783
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
551176
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
48676
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
7325
apdn Unrealized Gain On Change In Fair Value Of Warrants
UnrealizedGainOnChangeInFairValueOfWarrants
4404000
apdn Unrealized Gain On Change In Fair Value Of Warrants
UnrealizedGainOnChangeInFairValueOfWarrants
613100
apdn Unrealized Loss On Change In Fair Value Of Warrants
UnrealizedLossOnChangeInFairValueOfWarrants
-394000
apdn Registered Direct Offering Costs
RegisteredDirectOfferingCosts
633198
apdn Loss On Issuance Of Warrants
LossOnIssuanceOfWarrants
1633767
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-8957
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
9507
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5624064
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3293070
CY2023Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1646000
CY2024Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
5071000
CY2024Q1 apdn Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Warrant Modification Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantModificationGainLossIncludedInEarnings
394000
CY2024Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
1765000
CY2024Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
5346000
CY2023Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
4285000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
5071000
apdn Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Warrant Modification Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantModificationGainLossIncludedInEarnings
394000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
4404000
CY2024Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
5346000
CY2024Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5635
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001410578-24-000733-index-headers.html Edgar Link pending
0001410578-24-000733-index.html Edgar Link pending
0001410578-24-000733.txt Edgar Link pending
0001410578-24-000733-xbrl.zip Edgar Link pending
apdn-20240331.xsd Edgar Link pending
apdn-20240331x10q.htm Edgar Link pending
apdn-20240331xex31d1.htm Edgar Link pending
apdn-20240331xex31d2.htm Edgar Link pending
apdn-20240331xex32d1.htm Edgar Link pending
apdn-20240331xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
apdn-20240331_def.xml Edgar Link unprocessable
apdn-20240331_lab.xml Edgar Link unprocessable
apdn-20240331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
apdn-20240331_cal.xml Edgar Link unprocessable
apdn-20240331x10q_htm.xml Edgar Link completed